Monoclonal antibodies directed against the epidermal growth factor receptor (EGFR) are proven to be active anti-tumor agents in colorectal cancer (CRC) and squamous cell carcinoma of the head and neck (SCCHN), either alone or combined with chemo- and/or radiotherapy. This evidence concerns the gene EGFR and neoplasm.